LBPH240816P35000
- 5.50
- +1.50+37.50%
Longboard Pharmaceuticals Newsroom
Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals
Express News | Longboard Pharmaceuticals Inc : Baird Raises Target Price to $60 From $36
Baird Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $60
Baird Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $60
Express News | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Top 3 Health Care Stocks That May Crash This Quarter
Express News | Citigroup Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $45
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Citi Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $45
Optimistic Buy Rating for Longboard Pharmaceuticals Amid Breakthrough Therapy Designation and Strong Market Potential
Express News | Longboard Pharmaceuticals Inc : Citigroup Raises Target Price to $45 From $40
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $80 From $57, Keeps Outperform Rating
Cantor Fitzgerald Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $90
Longboard Pharmaceuticals Advancing DEE Treatment Trials
Express News | Longboard Pharmaceuticals Inc - to Initiate Global Phase 3 Program Later This Year
Express News | Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
Longboard Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Express News | Longboard Pharmaceuticals Inc : Evercore ISI Raises Target Price to $57 From $44
Express News | Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $57 From $44, Maintains Outperform Rating